Compare · DXCM vs MMED
DXCM vs MMED
Side-by-side comparison of DexCom Inc. (DXCM) and MiniMed Group Inc. (MMED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MMED operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 5.8x MMED ($4.73B).
- Over the past year, DXCM is down 20.1% and MMED is down 8.0% - MMED leads by 12.1 points.
- MMED has been more active in the news (11 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 12 for MMED).
- Company
- DexCom Inc.
- MiniMed Group Inc.
- Price
- $71.54+1.52%
- $16.80+2.85%
- Market cap
- $27.61B
- $4.73B
- 1M return
- +2.57%
- +18.81%
- 1Y return
- -20.08%
- -8.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2026
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 12
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest MMED
- MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries
- MiniMed to Announce Its Fiscal Year 2027 First Quarter Financial Results
- SEC Form 3 filed by new insider Endicott David J.
- SEC Form 3 filed by new insider Burman Linnea
- SVP, Gen. Counsel, Corp. Sec. Wills Courtney Nelson was granted 82,787 shares, increasing direct ownership by 150% to 138,146 units (SEC Form 4)
- VP, Chief Accounting Officer Gyurci John was granted 24,244 shares, increasing direct ownership by 154% to 39,941 units (SEC Form 4)
- SVP, Chief HR Officer Chandrasena Gillian was granted 44,188 shares, increasing direct ownership by 34% to 174,844 units (SEC Form 4)
- EVP, Chief Financial Officer Spooner Chad was granted 116,607 shares, increasing direct ownership by 43% to 386,008 units (SEC Form 4)
- Officer Dianaty Ali was granted 131,312 shares, increasing direct ownership by 68% to 323,170 units (SEC Form 4)
- Chief Executive Officer Dallara Que was granted 297,618 shares, increasing direct ownership by 48% to 916,099 units (SEC Form 4)